ArticleFrontiers in oncology2025
Analyzing the impact of human leukocyte antigen mismatch on the incidence of prostate cancer and the advantage of T cell therapy in patients after kidney transplantation based on the United Network for Organ Sharing database.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prostate cancer initially misdiagnosed as prostatic abscess in a 36-year-old kidney transplant recipient.Current therapeutic research, clinical and experimental · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: We aim to analysis the impact of Human Leukocyte Antigen (HLA) mismatch between kidney transplant donors and recipients on the incidence of prostate cancer after kidney transplantation (KT). Meanwhile, understanding the use of T cell therapy is of great importance after kidney transplantation from the perspective of prostate cancer occurrence. Methods: A retrospective study was conducted on kidney transplant recipients based on the United Network for Organ Sharing (UNOS) database from 2000 to 2019. General demographic data, socio-economic and educational data, personal medical history, immunosuppressive therapy regimens, and HLA typing of donors and recipients were collected to analyze the impact of: (1) baseline patient characteristics; (2) HLA mismatch; and (3) HLA subtype mismatch on the incidence of prostate cancer after transplantation. Results: A total of 268-994 kidney transplant recipients were included, with 1-910 newly diagnosed prostate cancer patients after surgery. Both univariate and Cox multivariate analysis discovered that the use of T cell therapy could reduce the risk of prostate cancer after KT [0.89(0.86~0.91)]. We also found HLA mismatch ≥ 3 is a risk factor of prostate cancer after transplantation [1.07(1.02~1.11)]. Further subgroup analysis was conducted on HLA mismatch. The Cox multivariate analysis of HLA-A (0-2), HLA-B (0-2), and HLA-DR (0-2) mismatch showed that 2-mismatch in HLA-A and HLA-B was a risk factor of prostate cancer after KT [1.19(1.01~1.40)]; 2-mismatch and 1-mismatch were both risk factors of prostate cancer after KT in the HLA-DR group [1.32(1.13~1.54)], [1.20(1.03~1.39)]. Conclusions: From the perspective of prostate cancer occurrence after transplantation, the use of T cell therapy is of great significance. HLA mismatch ≥ 3 was a risk factor of prostate cancer after KT. HLA-A and HLA-B 2-mismatch were risk factors of prostate cancer after KT, while HLA-DR 1-mismatch and 2-mismatch were both risk factors of prostate cancer after KT. This research contributed to the focus on the relationship between induction therapy and cancer occurrence after KT, and also provide guidance for reasonable selections of HLA typing of prostate cancer before KT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.